Cousins have contributed equally to this paper. . Selected studies were published in the English language, included cases of schizophrenia and related psychotic disorders, and were observational, clinical trial, case series or case report by design. Studies that did not report primary data, such as reviews or trial protocols were excluded. Studies of anti-inflammatory agents in disorders other than psychosis were also excluded. Electronic search identified 157 studies, of which 19 were selected after screening of title, abstract, and examination of full article content (see Table 1 ).
Introduction
Complex immune-brain interactions that affect neural development, survival, and function may have aetiological and therapeutic implications for a number of disorders of the central nervous system (CNS), [1] [2] [3] [4] [5] including psychiatric illness. 2 Multiple sclerosis, previously considered to be solely neurological, is increasingly recognised as secondary to immune dysfunctions. 3 Higher levels of the circulating proinflammatory cytokine interleukin (IL) 6 in childhood have been reported to be associated with increased risks of subsequent psychosis and depression in young adult life; 2 while elimination of auto-antibodies against neuronal cell surface proteins by immunotherapy has led to symptomatic improvement in some cases of first episode psychosis. 6 This review considers whether we are entering a new era of immuno-psychiatry that will change our understanding of the brain's maladies where manifestations include, but are rarely restricted to, mental symptoms. Accumulating evidence, of considerable breadth and depth, supports a role for immune system in the pathogenesis of depression and schizophrenia, which is consistent with the well-known clinical and aetiological (including genetic) overlap between these disorders. In this review, we highlight some of the important areas of research implicating the innate and adaptive immune response in the pathogenesis of schizophrenia and related psychotic disorders through effects on neurotransmitters, neurodevelopment, and degeneration. We discuss potential therapeutic implications of these findings as well as existing treatment studies of anti-inflammatory agents in schizophrenia.
The aim of this review is not only to summarise key evidence regarding the link between immune system and schizophrenia but also to identify gaps in knowledge, and to provide suggestions for improvement including testable hypothesis for future investigations. The aim 5 is also to give a holistic view, rather than an exhaustive review, of a landscape that may be of increasing relevance to people with schizophrenia and those who treat them.
The immune system and the brain share some fundamental characteristics. Both are highly integrated, complex systems with memory that develop through interactions with the external environment, able to distinguish between self and non-self, and respond adaptively. 7, 8 Historically, the brain has been considered as an immunologically privileged site shielded behind the blood-brain-barrier (BBB), 9 but immune components of the brain, such as microglia that constitute about 10% of the brain cell mass (equal to neurons), derive from the haematopoietic system beyond the CNS. 10 In response to systemic inflammation, microglia release cytokines which bind to specific receptors on neurons, 8 and affect neurotransmitters, synaptic plasticity, and cortisol levels, leading to changes in mood, cognition, and behaviour. 1, 5 In the following section, we briefly summarise epidemiological and genetic studies that suggest a link between inflammation, immunity, and psychosis. Next, we review specific abnormalities of the immune system seen in schizophrenia and related psychosis. Finally, we discuss the potential role of these changes in pathogenesis and treatment of psychotic illness including existing studies of anti-inflammatory agents in schizophrenia.
The immune and infection link to psychosis
The immune system consists of a complex organisation of cells and mediators which has evolved largely to protect us from infection and malignancy. 8 It can be broadly conceptualised as consisting of an innate response, acting as a rapid, non-specific, first line of defence, and an adaptive response that is slower and antigen specific. 
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Childhood auto-immune conditions are associated with sub-clinical psychotic experiences in adolescents 21 and schizophrenia in adults. 22 The prevalence of auto-immune conditions is increased in people with schizophrenia and their unaffected first degree relatives. 23 Besides, risk of schizophrenia increases in a linear fashion with the number of severe infections in individuals with a previous history of auto-immune disease. 22 Thus, the links between schizophrenia and a range of infections and autoimmune conditions suggest a common underlying pathway, most likely involving the inflammatory immune response. In addition to its own effects on the brain, inflammation is thought to increase the permeability of the BBB and to facilitate penetration of immune components into the brain. 24 8
Support for an immune-mediated aetiology in schizophrenia comes from genome wide association studies (GWAS), reporting significant associations between schizophrenia and markers close to the major histocompatibility complex (MHC) region on chromosome six. 25, 26 This region contains many immune-related genes, including those involved in antigen presentation and inflammatory mediators. A recent GWAS has identified 108 genetic loci (83 previously undetected) associated with schizophrenia: broadly, these represent genes expressed in the brain, and immune cells involved in adaptive immunity (CD19 and CD 20 B-lymphocytes) as well as the MHC. 27 Moreover, associations for the immune related genes remained significant after the MHC region was excluded suggesting these findings were not driven by the strong association at the MHC. Another GWAS found significant genetic overlap involving the MHC region between schizophrenia and multiple sclerosis, a condition characterised by immune dysfunction.
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The immune system in the pathogenesis of schizophrenia and related psychosis We have highlighted these issues along with suggestions for development in relevant sections. Despite these lacunae in the literature, current knowledge is consistent with a role for the immune system in the pathophysiology of schizophrenia and related psychotic disorders.
Text box 2: A few key research questions regarding immunological aspects of schizophrenia, related psychosis and other mental illness
1. Is elevated serum concentration of proinflammatory cytokines a cause or consequence of schizophrenia? 2. Could systemic inflammatory markers be used to identify prodromal cases of schizophrenia, to predict disease progression, response to antipsychotic treatment and recovery? 3. Could inflammatory processes explain cognitive deficits, progressive cognitive decline and brain volume loss in some cases of schizophrenia? 4. Could inflammatory processes explain the association between early-life adversity and risk of psychiatric disorders in adult life? 5. Does activation of microglia correspond with clinical severity of schizophrenia and response to antipsychotic treatment? 6. What is the role of neuronal cell surface auto-antibodies in schizophrenia and other psychiatric disorders? 7. What is the prevalence of neuronal cell surface antibodies in schizophrenia, other psychiatric disorders and healthy controls? 8. Does the prevalence of neuronal cell surface antibodies depend on the phase of the illness? Are there clinical signs that predict a positive test? 9. Are there other peripheral biomarkers associated with neuronal cell surface antibodies which could form therapeutic targets? 10. What is the relationship between intestinal microbiota and inflammatory, behavioural, cognitive and neurochemical phenotypes seen in schizophrenia and other psychiatric disorders? 11. What is the response of antibody associated psychosis to immunosuppression or antipsychotic treatment? 12. Does controlling inflammation lead to clinical improvement in psychosis and other mental illness? 13. Is stratification of patients based on their immune phenotype helpful with regards to predicting response to conventional and/or novel treatments?
Inflammatory cytokines
Meta-analyses of many cross-sectional studies show that schizophrenia is associated with disruption of the cytokine milieu and the propensity for the production of proinflammatory cytokines. 16, 29, 30 Longitudinal studies of inflammatory markers and subsequent psychotic disorders are scarce. Recent findings from the ALSPAC birth cohort suggest that higher serum levels of the proinflammatory cytokine IL-6 at age 9 years confers a two-fold risk of developing psychotic disorder at age 18 years. 2 The study also reports a robust, dose-response relationship between higher IL-6 levels in childhood and subsequent risk of sub-clinical psychotic experiences in young adulthood, which persists after taking into account a number of potential confounders including gender, body mass, and psychological and behavioural problems preceding the measurement of childhood IL-6. 2 No associations between serum CRP levels at baseline and future psychiatric disorders were observed, but another longitudinal study reported increased risk of late or very late onset schizophrenia for higher serum CRP levels at baseline. 31 Further longitudinal studies are needed to confirm whether the increase in serum levels of proinflammatory cytokines in schizophrenia and related psychosis is the cause or consequence of illness, though these findings suggest they point towards causal mechanisms.
Antipsychotic naïve first episode psychosis 30 and acute psychotic relapse 16 are also associated with increased serum levels of IL-6 and other proinflammatory cytokines, such as tumour necrosis factor alpha (TNF-α), interferon gamma (IFN-γ), and decreased serum levels of anti-inflammatory cytokine IL-10, which are normalised after remission of symptoms with antipsychotic treatment. 16 Reduced IL-2 production in vitro by T cells collected from schizophrenia patients has been reported, 32 but acute psychosis is associated with no significant changes in serum IL-2 levels. 16 There is an increase in levels of soluble IL-2 receptor (sIL-2R), 16, 30 which is likely to be a compensatory mechanism inhibiting IL-2 production. Thus, the data are consistent with an increase in proinflammatory cytokines in acute psychosis. However, a few studies have adjusted for important immune-modulatory factors such as body mass or smoking, 16 or examined cytokines in CSF where increase in IL-6 33, 34 has been reported in schizophrenia. One study has reported increased serum IL-6 concentration in people with at-risk mental state for psychosis compared with healthy controls. 35 Some data suggest that serum cytokine concentrations including IL-6 are associated with illness severity, duration, and antipsychotic therapy, 16 , 36, 37 but we know little regarding the associations between stress, cortisol and cytokine levels in different stages of schizophrenia. Therefore, more studies are required to understand the relationships between cytokine levels, disease prodrome, progression and treatment response. Longitudinal studies of first episode psychosis, individuals at clinical high risk for developing psychosis as well as those with treatment refractory illness would be useful to examine these issues. Rather than merely demonstrating group differences in cytokine serum or CSF levels, future studies should examine associations between cytokines, cognitive and social functioning, comorbid physical illness, and structural and functional brain indices in people with psychosis and healthy controls.
In rodents studies have demonstrated physiological roles of cytokines in memory and learning, including long-term potentiation, synaptic plasticity and neurogenesis (for review see). 38 Recently, mild systemic inflammation has been reported to produce impairments in spatial memory in humans via its action on glucose metabolism in the medial temporal lobe. 39 Whether cytokine-mediated inflammatory processes underlie cognitive dysfunction in schizophrenia, an integral part of the syndrome, is an important hypothesis that requires investigation.
Longitudinal associations between IL-6 and both psychosis and depression may indicate a trans-diagnostic effect. 2 A longitudinal association between serum C-reactive protein, a marker of systemic inflammation, and subsequent symptoms of post-traumatic stress disorder has been reported. 40 Thus, understanding the early-life bio-psycho-social determinants of cytokine serum concentrations would be crucial in order to elucidate whether increased levels of cytokines could explain the association between early-life adversity and the risk of various psychiatric illnesses in adulthood. 41 Studies using mouse models have demonstrated how peripheral cytokines, such as IL-6, can affect the brain (figure 1) (for reviews see). 1, 4 Circulating IL-6 binds to receptors on the vagus nerve, and the signal reaches hypothalamic brain nuclei via brainstem by retrograde axonal transport. Once within the CNS, the cytokine signal is amplified, which activates microglia, leading to the secretion of proinflammatory cytokines, chemokines, and proteases within the brain. 1 These messengers activate indoleamine 2, 3 dioxygenase, an enzyme that metabolizes tryptophan along the kynurenine pathway, leading to increased levels of kynurenic acid and its metabolite quinolonic acid, both of which are involved in glutamatergic neurotransmission. 42 Cytokines also increase oxidative stress by raising the concentration of toxic nitric oxide, and activate the hypothalamic-pituitary-adrenal axis leading to the release of cortisol. 1, 5 These effects could contribute to the negative, cognitive and positive symptoms of schizophrenia, as well as to impaired mood, cognition, and perception that are important parts of other psychiatric disorders. Indeed non-specific peripheral immune activation caused by injection of lipopolysaccharide in healthy volunteers increases serum IL-6 levels as well as inducing low mood, anxiety and reduced cognitive performance. 43 Furthermore, cytokines have significant effects on microglia that, in turn, are crucial for the maintenance of effective neuronal and synaptic health. Neuroinflammation is characterised by the activation of microglia cells, which show an increase in the expression of the peripheral benzodiazepine receptor. Neuroimaging studies using positron emission tomography and a peripheral benzodiazepine receptor ligand provide evidence for neuroinflammation in recent onset schizophrenia, 47 and in acute exacerbations of schizophrenia. 48 They indicate increased binding of this ligand in the entire grey matter and the hippocampus, suggesting that neuroinflammation might contribute to grey matter volume loss and cognitive deterioration in schizophrenia. 47, 48 However, such studies are limited in 14 number and the existing studies have included small numbers of people with schizophrenia and healthy controls. An alternative explanation for increased binding of the benzodiazepine receptor ligand could be its affinity for activated astrocytes, which are seen in schizophrenia but are unrelated to neuroinflammation. 48 Many patients with schizophrenia are treated with benzodiazepines, which can also influence binding of this ligand. Thus, there is a need for identifying reliable markers of microglial activation that can be used for in vivo imaging or measured in blood in order to investigate whether microglial activation corresponds with clinical severity and treatment response.
Previously activated microglia may respond more strongly to a new stimulus. 49 Microglia are likely to retain an immune memory of the neuropathology, which, in turn, is associated with heightened responsiveness to new systemic inflammation. 46 Thus, early developmental insults such as childhood CNS or severe systemic infection may have a priming effect on microglia, 49 increasing microglial activation and psychosis risk following subsequent infections. Whether the association between early-life CNS infection and adult schizophrenia 14 could be explained by changes in microglia can be tested using longitudinal birth cohorts. Induced pluripotent stem cell technology has been successfully used to create neurons by reprogramming human fibroblast cells: neurons derived from schizophrenia patients have diminished neuronal connectivity, decreased neurite number and glutamate receptor expression compared with neurons derived from healthy controls. 50 It remains to be seen whether this technology can be utilized to study non-neuronal brain cells such as microglia.
Anti-neuronal cell surface auto-antibodies
A possible role of brain reactive auto-antibodies in the aetiology of schizophrenia has been discussed since the early twentieth century. 51 59 It remains to be tested whether this is also the case for patients with antibodies and a purely psychiatric presentation, although there are a few case descriptions to support this. 6 Randomised controlled trials (RCT) of immuno-therapy as an adjunct of standard antipsychotic treatment for antibody-associated cases of psychosis are required to examine this question.
It is possible that NMDAR antibody seropositivity in some people with psychosis is in fact undiagnosed anti-NMDAR encephalitis. However, it has been argued that diagnostic misclassification is unlikely to be the sole explanation for this because almost none of the NMDAR antibody seropositive cases of psychosis has IgG class NMDAR antibodies against the NR1 subunit alone (one of the subunits of the NMDAR antibody). 57, 60 An association between NMDAR antibody and schizophrenia is biologically plausible. In healthy volunteers, NMDAR blockade with ketamine produced psychotic symptoms. 61 Furthermore, a recent study has shown that de novo mutations, in the form of chromosomal copy number changes, affect glutamatergic post-synaptic proteins that form part of the NMDAR. 62 NMDAR antibody seropositivity is not limited to patients with schizophrenia alone. Patients with psychiatric disorders such as schizophrenia, depression, and bipolar disorder are collectively about three times more likely to have elevated NMDAR antibody titers compared with controls based on high-specificity (but not low-specificity) seropositivity thresholds. 60 This underscores the need for further cross-sectional and longitudinal studies of psychiatric cases and healthy controls employing standardized assay methods and seropositivity threshold definitions. Preclinical studies are also needed to elucidate pathogenic mechanisms of these antibodies in psychosis and other mental illness.
T lymphocytes
T cells are thymus derived lymphocytes which, very simply, can be considered as either 'CD8 expressing' cytotoxic cells or 'CD4 expressing' helper cells, and may have both proinflammatory and anti-inflammatory roles. Recent evidence suggests a role for T cells in the aetiology of schizophrenia. Acute psychosis is associated with the activated phenotype of lymphocytes within the CNS compared with controls. 63 In post mortem studies, immunohistology has allowed direct visualisation of increased T cell as well as B cell numbers within the hippocampus in patients with schizophrenia. 64 These changes were particularly evident in those with predominantly negative, compared with positive symptoms. 65 However, there are inconsistencies between studies as to whether schizophrenia is associated with increased or decreased numbers of lymphocytes in the peripheral circulation. A recent meta-analysis has reported increased numbers of cells positive for CD56
(a marker of natural killer cells and activated T cells), and a higher CD4/CD8 T cell ratio in schizophrenia. 66 It also highlighted important limitations of the existing data. Many studies do not control for immune-mediating variables, such as smoking, body mass, stressassociated cortisol levels, and medication. Findings from individual studies are difficult to compare because they report percentages rather than cell numbers.
Well-controlled studies reporting absolute cell numbers are required to fully understand any associations between T cells and schizophrenia. Since schizophrenia is a heterogeneous condition, one might speculate that different T cell subtypes are associated with differing symptomatology. Thus studies of T cells after stratification of cases by symptom profile may be more informative. In order to fully understand the role of T cells in schizophrenia, an understanding of the function of these cells is also required. Future studies should assess the cytokine profile of these cells, their activation status, and gene expression profile.
How might immune dysregulation lead to the manifestation of schizophrenia?

Effects on neurotransmitters
Studies in animal models suggest an association between prenatal infection/ inflammation and disturbance of neurotransmitter systems (glutamate, dopamine and GABA) in the offspring, 67 but little is known about the direct effects of the inflammatory immune response on neurotransmitter systems in humans. NMDAR antagonism and glutamatergic hypofunction have long been proposed as underlying mechanisms for psychotic symptoms and cognitive dysfunction in schizophrenia. 61, 68 There is evidence that proinflammatory cytokines increase the concentration of kynurenic acid, which is a metabolite of tryptophan and the only naturally occurring NMDAR antagonist in the human CNS (figure 2).
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Figure 2: Possible mechanisms of immune-mediated aetiology of psychosis
Studies of the cyclooxygenase (COX) pathway may lead to a better understanding of the role of kynurenic acid in psychosis. COX-1 inhibition increases levels of kynurenic acid while COX-2 inhibition decreases them. 71 This might explain some of the side effects of COX-1 inhibitors, such as psychotic symptoms and cognitive dysfunction. On the other hand, Celecoxib (a selective COX-2 inhibitor) has been reported to improve clinical symptoms in schizophrenia. 72, 73 Thus, systematic evaluation of the neuropsychiatric side-effects of COX-1 and COX-2 inhibitors from existing RCT data would be useful.
The relationship between neurotransmitters and immune mediators may be reciprocal with a few publications reporting immunoregulatory functions for dopamine; for review see. 74 T cells express dopamine receptors, the stimulation of which promotes up-regulation of adhesion molecules and cytokine production. 75, 76 Increased expression of the dopamine D3 receptor and increased synthesis of the pro-inflammatory cytokine IFN-γ by lymphocytes have been reported in un-medicated patients with schizophrenia. 77 The opposite has been observed in Parkinson's disease, 78 a condition characterised by CNS dopamine depletion.
Further studies are required to understand the effects of inflammation on neurotransmission and vice versa in healthy people and those with psychiatric disorders.
Effects on neurodegeneration
Progressive clinical deterioration, cognitive decline, loss of cortical grey matter along with histopathological evidence of neuronal atrophy and reductions in the number of neuronal synapse and dendrites, all suggest a neurodegenerative process is active in schizophrenia beyond that seen in healthy subjects. [79] [80] [81] Activated microglia are increasingly being recognised as an important component in the pathogenesis of other degenerative brain conditions, such as Alzheimer's disease, where they appear to have wide ranging effects. 46 Is this also the case in schizophrenia? Microglial activation interferes with neuronal survival by increasing oxidative stress and decreasing neurotrophic support. 5 Schizophrenia is associated with changes in serum, plasma, and red blood cell markers of oxidative stress. 82 Recently a population-based longitudinal study has reported a strong association between delirium and subsequent dementia and cognitive decline in older adults, which is not mediated by classical neuropathologies associated with dementia. 83 It is possible systemic inflammation, a common cause of delirium, underlies this association. Indeed severe systemic illness in the elderly has been reported to be associated with subsequent cognitive decline and functional deterioration. 84, 85 In the future, studies should examine whether inflammatory processes could explain progressive cognitive decline and brain volume loss in some cases of schizophrenia.
Effects on neurodevelopment
Interference with brain development from early-life infection/inflammation is consistent with a neurodevelopmental view of schizophrenia. 86, 87 Given the association of adult schizophrenia with a variety of early-life infections, (for reviews see) 14, 15 it is likely that a common pathway, the proinflammatory immune response, is involved. This notion is supported by animal model studies. Simulated viral or bacterial infection or direct injection 20 with IL-6 in pregnant mice has been reported to produce intermediate phenotypes related to schizophrenia in the adult offspring. 88 Some of these phenotypes, such as deficits in sensory gating and abnormal latent inhibition, are reversible by treatment with clozapine. 89 Since infections are widespread in the general population, interactions with genetic or other factors are likely. Indeed an additive effect of family history of psychosis and prenatal infection in the causation of schizophrenia has been reported in a Finnish cohort. 90 In the future studies should examine gene-infection interaction, and whether there is a 'sensitive period' during development when exposure to infection is more harmful.
GWAS and epidemiological studies indicate some overlap of genetic susceptibility between schizophrenia and serious infection. The vagus nerve, which plays a central role in relaying the systemic cytokine signal to the brain (discussed above), may be also important for gut-brain communication. In mice, anxiolytic and antidepressant effects of feeding a specific strain of Lactobacillus can no longer be seen after vagotomy. 95 There is evidence of greater intestinal inflammation in individuals with schizophrenia compared with controls, and similarly, in people with first episode psychosis who have not taken antipsychotics compared with those receiving antipsychotics. 96 Studies in animals 97 and humans 98 suggest that manipulation of the gut microbial composition influences systemic cytokine levels. Thus, it is possible that intestinal microbiota affect the brain and behaviour by influencing systemic cytokine levels in schizophrenia. This is an important hypothesis that warrants examination. In the future, studies should examine the relationships between intestinal microbiota and behavioural, cognitive and neurochemical phenotypes in psychiatric disorders and healthy controls.
Therapeutic implications of an immunological and inflammatory understanding of schizophrenia and other mental disorders
Current understanding of the association between the immune system and risk of psychotic disorders hold promise for novel approaches for detection, treatment and prevention. These may include developing or 'repurposing' drugs to target inflammatory pathways, immunotherapy for antibody-associated cases of psychosis and other mental illness, and stratification of patients by their immune phenotype in order to inform treatment decision and to measure treatment response. Indeed, a recent molecular study has reported two distinct subgroups of schizophrenia patients characterised by predominant abnormalities in either immune molecules or growth factors and hormones. 99 RCTs of anti-inflammatory agents as adjunct to standard therapy have shown promising results in schizophrenia (table 1) , although such trials are few and have often involved small samples. 100 Celecoxib has been reported to improve cognitive function in early stages of schizophrenia, 101, 102 but the use of COX-2 inhibitors is problematic as they can increase risk of heart disease. 103 Recently, Minocycline, a centrally acting tetracyclic anti-inflammatory agent, has been reported to improve negative symptoms and cognitive function in schizophrenia. 104, 105 Large multi-centre trials are required, with stratification of patients by their immune phenotype. This approach proved useful in a recent RCT of infliximab (a TNF-α antagonist) in treatment-resistant depression, in which no overall efficacy was observed but it improved depressive symptoms in patients with high concentrations of inflammatory markers at the start of the trial. 106 It has been suggested that lack of clinical benefit from conventional antidepressants may be related to activation of the inflammatory system. 107 In the future, RCTs should focus on specific patient groups characterised by, for example, resistance to conventional antipsychotics, presence of a defined pattern of immune activation, such as a predominantly proinflammatory molecular signature, or symptom profile, such as predominant negative symptoms or cognitive dysfunction.
Identification of specific inflammatory pathways for neuropsychiatric symptoms would provide novel targets for therapeutic intervention. 108 Animal studies suggest a mechanistic role of quinolonic acid, an NMDAR agonist, for inflammation-induced depression. 42 Indeed
RCTs of NMDAR antagonists, ketamine and compound AZD6765, have shown promising results for treatment resistant depression. [109] [110] [111] Whilst safety and tolerability of ketamine may limit its applicability in clinical setting, these findings provide further support for a role of inflammation in major mental illness.
New therapeutics for immunologically stratified psychosis might be based on molecules and targets that are already well known in other therapeutic areas, allowing 'repurposing' of existing anti-inflammatory agents. 112 Collaboration between industry and academia would be important to realise the potential of immune modulatory agents for the treatment of major mental illness. In the future studies should assess the prophylactic potential of immunological agents in individuals at high risk of developing psychosis. Longitudinal associations between higher levels of IL-6 and subsequent risks of psychosis, 2 depression, 2 heart disease, 113 and type-two diabetes 114 suggest that controlling inflammation might reduce the risk of a number of chronic adult diseases, and thus, have a huge beneficial effect at the population level.
Conclusion
Inflammation and immune dysfunction might contribute to cognitive, negative and positive symptoms in schizophrenia. We have highlighted several hypotheses and potential areas of interest for future research regarding the immunological aspects of schizophrenia. Addressing these issues would contribute to understanding disease mechanism and the development of effective new interventions, but requires integrated working between several disciplines.
While animal model studies have much to offer in terms of understanding specific biological systems, these findings need to be confirmed in human subjects. This highlights the scope for translational research in schizophrenia over the coming years encompassing immune, genetic, microbiological, and other biomarkers.
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